The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TR-1: Notification of Major Interest in Shares

2 Aug 2012 12:12

For filings with the FSA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying Silence Therapeutics plc issuer of existing shares to which voting rights are attached: ii

2 Reason for the notification (please tick the appropriate box or boxes):An acquisition or disposal of voting rightsAn acquisition or disposal of qualifying financial instruments which mayresult in the acquisition of shares already issued to which votingrights are attachedAn acquisition or disposal of instruments with similar economic effectto qualifying financial instrumentsAn event changing the breakdown of voting rightsOther (please specify):

3. Full name of person(s) subject to the Simpson Financial Limited notification obligation: iii

4. Full name of shareholder(s) (ifdifferent from 3.):iv5. Date of the transaction and date on 2 August 2012which the threshold is crossed orreached: v6. Date on which issuer notified: 2 August 20127. Threshold(s) that is/are crossed or below 3%

reached: vi, vii

8. Notified details:

A: Voting rights attached to shares viii, ixClass/type of Situation previous to Resulting situation after the triggeringshares if the triggering transactionpossible using transactionthe ISIN CODE Number of Number of Number of Number of voting % of voting rights Shares Voting shares rights x Rights Direct xi Direct Indirect Direct Indirect xiiGB0008433350 25,000,000 25,000,000 33,073,055 33,073,055 2.26%B: Qualifying Financial InstrumentsResulting situation after the triggering transactionType of financial Expiration Exercise/ Number of voting % of votinginstrument date xiii Conversion Period rights that may be rights xiv acquired if the instrument is exercised/ converted.N/AC: Financial Instruments with similar economic effect to Qualifying Financial Instrumentsxv, xviResulting situation after the triggering transactionType of Exercise Expiration Exercise/ Number of voting % of voting rightsfinancial price date xvii Conversion rights instrument xix, xxinstrument period refers to xviiiN/A Nominal Delta Total (A+B+C)Number of voting rights Percentage of voting rights33,073,055 2.26%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to holdvoting rights:13. Additional information:14. Contact name: Eric K. Simpson15. Contact telephone number: 852 2520 2066

Note: Annex should only be submitted to the FSA not the issuer

Annex: Notification of major interests in sharesxxii

A: Identity of the persons or legal entity subject to the notification obligation Full name (including legal form of legal Simpson Financial Limited entities) Contact address (registered office for Wyndham Place 26th Floor, 44 Wyndham legal entities)

Street, Central, Hong KongPhone number & email 852 2520 2066 sfl@simpsonfinancial.comOther useful information (at least legalrepresentative for legal persons)B: Identity of the notifier, if applicableFull nameContact addressPhone number & emailOther useful information (e.g. functionalrelationship with the person or legalentity subject to the notificationobligation)

C: Additional information

For notes on how to complete form TR-1 please see the FSA website.

XLON
Date   Source Headline
28th Jun 20192:06 pmRNSAdditional Listing
25th Jun 201912:09 pmRNSResult of AGM
24th Jun 20191:20 pmRNSHolding(s) in Company
21st Jun 20192:36 pmRNSHolding(s) in Company
20th Jun 20191:36 pmRNSHolding(s) in Company
20th Jun 20191:00 pmRNSHolding(s) in Company
19th Jun 20199:16 amRNSHolding(s) in Company
18th Jun 20194:37 pmRNSHolding(s) in Company
18th Jun 20191:37 pmRNSHolding(s) in Company
18th Jun 201912:28 pmRNSAdditional Listing
28th May 20197:00 amRNSCollaboration with Genomics England
20th May 20194:46 pmRNSAdditional Listing
14th May 20193:00 pmRNSAdditional Listing
30th Apr 20197:00 amRNSAdditional Listing
26th Apr 20192:35 pmRNSAdditional Listing
25th Apr 20194:55 pmRNSAdditional Listing
25th Apr 20197:00 amRNSSilence Therapeutics Announces Board Changes
18th Apr 20197:00 amRNSAppointment of Chief Financial Officer
18th Apr 20197:00 amRNSSilence Therapeutics Publication of Annual Report
16th Apr 201911:00 amRNSSilence Therapeutics Announces Board Change
16th Apr 20197:00 amRNSSilence Therapeutics appoints Head of R&D and CMO
4th Apr 20199:09 amRNSHolding(s) in Company
27th Mar 20197:00 amRNSSilence Therapeutics submits CTA for SLN124
11th Mar 20197:00 amRNS2018 Preliminary Results
7th Mar 20197:00 amRNSSilence to Present at Cowen Healthcare Conference
5th Mar 20197:00 amRNSNotice of Results
4th Mar 20193:35 pmRNSHolding(s) in Company
26th Feb 20195:24 pmRNSHolding(s) in Company
1st Feb 20194:40 pmRNSSecond Price Monitoring Extn
1st Feb 20194:35 pmRNSPrice Monitoring Extension
15th Jan 20197:00 amRNSSLN124 granted Orphan Drug Designation by EMA
9th Jan 20197:00 amRNSDeparture of Chief Financial Officer
19th Dec 20187:00 amRNSSilence Therapeutics advances next RNAi medicine
18th Dec 20184:35 pmRNSPrice Monitoring Extension
10th Dec 20187:00 amRNSSettlement and License Agreement with Alnylam
12th Oct 20186:29 pmRNSErratum: Results of Placing - Withdrawn
12th Oct 20185:12 pmRNSResults of Placing
11th Oct 201810:14 amRNSPTAB Upholds Silence Patent
10th Oct 20187:00 amRNSNew divisional patent and injunction application
5th Oct 20182:16 pmRNSHolding(s) in Company
26th Sep 20187:00 amRNSSilence to Present at Healthcare Conference
21st Sep 20182:19 pmRNSAdditional Listing
11th Sep 20187:00 amRNSInterim results for six months ended 30 June 2018
30th Aug 201810:53 amRNSHolding(s) in Company
30th Aug 201810:46 amRNSHolding(s) in Company
24th Aug 20187:00 amRNSNotice of Results
20th Aug 20189:30 amRNSSilence Therapeutics Announces Board Change
7th Aug 20187:00 amRNSLitigation: patisiran EU MA imminent
17th Jul 20183:00 pmRNSDirector/PDMR Shareholding
17th Jul 20181:00 pmRNSAppoints David Horn Solomon as CEO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.